Displaying 1 - 12 of 12
Metabolism, Alcohol & Toxicity
1

Novo Nordisk and Echosens: "Clinical challenge: Updates on the non-invasive toolbox for NASH and Fibrosis" - EASL Congress 2023

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
Metabolism, Alcohol & Toxicity
6

Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021

View
Metabolism, Alcohol & Toxicity
6

Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021

View
Metabolism, Alcohol & Toxicity
6

Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021

View
Metabolism, Alcohol & Toxicity
6

Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021

View
Metabolism, Alcohol & Toxicity
6

Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021

View
Metabolism, Alcohol & Toxicity
6

Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021

View
Displaying 1 - 12 of 12